背景:伴随诊断和分子靶向治疗剂领域的最新进展有助于开发针对胃癌(GC)和食管胃结合部癌(EGJC)的人表皮生长因子受体2(HER2)的治疗方法。而准确诊断HER2表达的重要性日益增加。然而,在GC和EGJC的报告中,HER2阳性率显着不同,和影响HER2阳性的因素需要阐明。
方法:本研究回顾性研究了单个机构中与HER2阳性相关的因素,包括年龄,性别,身体质量指数,美国麻醉医师协会的身体状况,肿瘤信息,和手术信息,包括标本处理的时间。
结果:我们的研究包括从2007年1月至2022年6月接受胃切除术的1,320例患者中使用GC和EGJC手术标本进行HER2测试的165例患者。总的来说,35例(21.2%)和130例(78.8%)患者为HER2阳性和阴性,分别。多因素分析显示肠型(比值比[OR]:3.41,95%置信区间[CI]:1.44-8.09,p=0.005),pM1(OR:3.99,95%CI:1.51-10.55,p=0.005),标本处理时间<120分钟(OR:2.65,95%CI:1.01-6.98,p=0.049)是影响HER2阳性的独立因素。
结论:本研究的结果表明,肠道类型,pM,标本处理时间是影响GC和EGJCHER2阳性率的重要因素。因此,通过缩短处理切除标本所需的时间,可以降低HER2结果假阴性的风险.此外,对HER2表达的准确诊断可能会增加给予分子靶向药物的机会,这些药物可以期望对患者产生适当的治疗效果.
背景:回顾性注册。
BACKGROUND: Recent developments in the field of companion diagnosis and molecular-targeting therapeutic agents have helped in developing treatments targeting human epidermal growth factor receptor 2 (HER2) in gastric cancer (GC) and esophagogastric junction cancer (EGJC), and the importance of accurate diagnosis of HER2 expression is increasing. However, the HER2-positivity rate significantly differs among reports in GC and EGJC, and factors that affect HER2-positivity require elucidation.
METHODS: The present study retrospectively examined factors related to HER2-positivity in a single institution, including age, sex, body mass index, the American Society of Anesthesiologists physical status, tumor information, and surgery information, including time to specimen processing.
RESULTS: Our study included 165 patients tested for HER2 using GC and EGJC surgery specimens among the 1,320 patients who underwent gastrectomy from January 2007 to June 2022. In total, 35 (21.2%) and 130 (78.8%) patients were HER2-positive and -negative, respectively. Multivariate analysis revealed that intestinal type (odds ratio [OR]: 3.41, 95% confidence interval [CI]: 1.44-8.09, p = 0.005), pM1 (OR: 3.99, 95% CI: 1.51-10.55, p = 0.005), and time to specimen processing of < 120 min (OR: 2.65, 95% CI: 1.01-6.98, p = 0.049) were independent factors that affected HER2-positivity.
CONCLUSIONS: The outcomes of the present study indicated that intestinal type, pM, and time to specimen processing are important factors affecting HER2-positive rates in GC and EGJC. Therefore, the risk of false-negative HER2 results may be reduced by decreasing the time required to process the resected specimen. Additionally, accurate diagnosis of HER2 expression may increase the opportunity to administer molecular-targeted drugs that can expect therapeutic effects to patients appropriately.
BACKGROUND: Retrospectively registered.